We are live on ! Find out more
UBX

Unity Biotechnology
UBX

Delisted

UBX was delisted on the 8th of July, 2025.

Back to rankings

55 hedge funds and large institutions have $258M invested in Unity Biotechnology in 2018 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 21 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 6

186% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 7

31% more funds holding

Funds holding: 42 → 55 (+13)

26% more capital invested

Capital invested by funds: $204M → $258M (+$53.2M)

0.73% more ownership

Funds ownership: 3.01% → 3.74% (+0.73%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
55
Holders Change
+13
Holders Change %
+30.95%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
20
Increased
21
Reduced
6
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$20M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$6.61M
3
Capital World Investors
Capital World Investors
California
+$5.65M
4
State Street
State Street
Massachusetts
+$4.19M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.83M

Top Sellers

Rank Fund Capital Flow
1
NTC
NF Trinity Capital
Hong Kong
-$9.9M
2
AG
Artal Group
Luxembourg
-$815K
3
Millennium Management
Millennium Management
New York
-$666K
4
Morgan Stanley
Morgan Stanley
New York
-$634K
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$183K
Name Holding Trade Value Shares
Change 		Change in
Stake
Cerity Partners
26
Cerity Partners
New York
$312K +$255K +1,920 New
VEA
27
Virtus ETF Advisers
New York
$309K +$252K +1,899 New
Bank of America
28
Bank of America
North Carolina
$297K +$224K +1,689 +1,270%
ProShare Advisors
29
ProShare Advisors
Maryland
$276K +$225K +1,697 New
AIG
30
American International Group
New York
$266K +$173K +1,304 +389%
DekaBank Deutsche Girozentrale
31
DekaBank Deutsche Girozentrale
Germany
$252K +$199K +1,500 New
CC
32
Callan Capital
California
$244K +$199K +1,500 New
Russell Investments Group
33
Russell Investments Group
United Kingdom
$226K +$183K +1,378 New
AllianceBernstein
34
AllianceBernstein
Tennessee
$225K +$184K +1,384 New
MIM
35
MetLife Investment Management
New Jersey
$196K +$160K +1,206 New
Susquehanna International Group
36
Susquehanna International Group
Pennsylvania
$177K +$145K +1,092 New
VOYA Investment Management
37
VOYA Investment Management
Georgia
$166K +$136K +1,024 New
MLICM
38
Metropolitan Life Insurance Company (MetLife)
New York
$144K +$117K +883 New
JP Morgan Chase
39
JP Morgan Chase
New York
$118K +$68.9K +519 +248%
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$111K – – –
Citigroup
41
Citigroup
New York
$107K +$69K +520 +374%
Legal & General Group
42
Legal & General Group
United Kingdom
$63K +$41.3K +311 +415%
AIP
43
Ameritas Investment Partners
Nebraska
$33K +$21.6K +163 +388%
SO
44
STRS Ohio
Ohio
$24K – – –
Barclays
45
Barclays
United Kingdom
$23K -$9.69K -73 -34%
Royal Bank of Canada
46
Royal Bank of Canada
Ontario, Canada
$13K -$2.65K -20 -20%
PRC
47
Pearl River Capital
Michigan
$12K +$9.69K +73 New
AWM
48
AllSquare Wealth Management
New York
$9K – – –
IA
49
IFP Advisors
Florida
$8K – – –
Daiwa Securities Group
50
Daiwa Securities Group
Japan
$7K +$5.31K +40 New
1
2
3

UBX Hedge Fund Activity: Q4 2018 in Review

55 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Unity Biotechnology (UBX) for Q4 2018, worth a combined $258M — up 26% from $204M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new UBX positions and 7 closed out — a net gain of 13 holders — while 21 added to existing stakes and 6 trimmed.

The largest buyer was BlackRock, adding an estimated $20M. The largest seller was NF Trinity Capital, exiting entirely with an estimated $9.9M sold.

  • 55 institutional investors held Unity Biotechnology (UBX) as of Q4 2018, up from 42 in Q3 2018.
  • Funds reported $258M of Unity Biotechnology stock for Q4 2018, up 26% quarter-over-quarter.
  • 20 funds opened new Unity Biotechnology positions in Q4 2018 and 7 closed out, a net change of +13 holders.
  • The largest Unity Biotechnology buyer in Q4 2018 was BlackRock, an estimated $20M added.
  • The largest Unity Biotechnology seller in Q4 2018 was NF Trinity Capital, an estimated $9.9M sold.

Based on aggregated 13F filings for Q4 2018.